Ann: EuGeni Test Strip Manufacturing Strategy, page-37

There is also another way of looking at Surges comments. Rather than sales not being forthcoming this is a belated strategy by the board to cover some of the potential demand. Closer examination of any supplier in the market is that Anteo's 8 to 20m may well inhibit getting any worthwhile sales. Think of how many people go through Heathrow each week. If a supplier cannot cover a customers requirement then there will be no sale. The Covid market is about who can supply. Can Anteo?

I am a very long time shareholder and believe in the technology. However, this action smacks of a late recognition by the board that supply is the key. This is something that should have been recognised 10 months ago. The delays due lack of recognition and poor forward thinking now mean Anteo has to break into the market. This now requires the best test and for it to be a saliva test.

For us all it is important to remember strategy is a board not management lead activity.